<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00433420</url>
  </required_header>
  <id_info>
    <org_study_id>GIM-2</org_study_id>
    <secondary_id>CDR0000528056</secondary_id>
    <secondary_id>EU-20681</secondary_id>
    <nct_id>NCT00433420</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer</brief_title>
  <official_title>A Phase III Randomized Study of EC Followed by Paclitaxel Versus FEC Followed by Paclitaxel, All Given Either Every 3 Weeks or 2 Weeks Supported by Pegfilgrastim, for Node Positive Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gruppo Italiano Mammella (GIM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as epirubicin, cyclophosphamide, paclitaxel, and&#xD;
      fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the&#xD;
      cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy)&#xD;
      may kill more tumor cells. Colony-stimulating factors, such as pegfilgrastim, may increase&#xD;
      the number of immune cells found in bone marrow or peripheral blood and may help the immune&#xD;
      system recover from the side effects of chemotherapy. Giving combination chemotherapy and&#xD;
      pegfilgrastim after surgery may kill any tumor cells that remain after surgery. It is not yet&#xD;
      known whether combination chemotherapy is more effective with or without fluorouracil and/or&#xD;
      pegfilgrastim in treating breast cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying combination chemotherapy to compare how&#xD;
      well it works when given with or without fluorouracil and/or pegfilgrastim in treating women&#xD;
      with node-positive breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the efficacy of adjuvant therapy comprising epirubicin hydrochloride,&#xD;
           cyclophosphamide, and paclitaxel with vs without fluorouracil and/or pegfilgrastim in&#xD;
           women with node-positive breast cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the overall survival of patients treated with these regimens.&#xD;
&#xD;
        -  Compare the safety of these regimens in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 4 treatment&#xD;
      arms.&#xD;
&#xD;
        -  Arm I: Patients receive epirubicin hydrochloride IV and cyclophosphamide IV on day 1.&#xD;
           Treatment repeats every 3 weeks for 4 courses. Patients then receive paclitaxel IV over&#xD;
           3 hours on day 1. Treatment with paclitaxel repeats every 3 weeks for 4 courses.&#xD;
&#xD;
        -  Arm II: Patients receive fluorouracil IV, epirubicin hydrochloride IV, and&#xD;
           cyclophosphamide IV on day 1. Treatment repeats every 3 weeks for 4 courses. Patients&#xD;
           then receive paclitaxel as in arm I.&#xD;
&#xD;
        -  Arm III: Patients receive epirubicin hydrochloride IV and cyclophosphamide IV on day 1&#xD;
           and pegfilgrastim subcutaneously (SC) on day 4. Treatment repeats every 2 weeks for 4&#xD;
           courses. Patients then receive paclitaxel IV over 3 hours on day 1 and pegfilgrastim&#xD;
           subcutaneously (SC) on day 4. Treatment with paclitaxel and pegfilgrastim repeats every&#xD;
           2 weeks for 4 courses.&#xD;
&#xD;
        -  Arm IV: Patients receive fluorouracil IV, epirubicin hydrochloride IV, and&#xD;
           cyclophosphamide IV on day 1 and pegfilgrastim SC on day 4. Treatment repeats every 2&#xD;
           weeks for 4 courses. Patients then receive paclitaxel and pegfilgrastim as in arm III.&#xD;
&#xD;
      In all arms, treatment continues in the absence of disease progression or unacceptable&#xD;
      toxicity. After completion of chemotherapy with or without pegfilgrastim, patients may&#xD;
      undergo external-beam radiation therapy at the discretion of treating center. Patients with&#xD;
      positive estrogen and/or progesterone receptor tumor receive tamoxifen for 5 years.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for 5 years and then&#xD;
      annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 2,000 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 2003</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pegfilgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed primary breast cancer&#xD;
&#xD;
               -  No histology other than carcinoma&#xD;
&#xD;
          -  Node-positive disease&#xD;
&#xD;
               -  Must have at least 1 involved axillary node or internal mammary node&#xD;
&#xD;
          -  Previously resected disease&#xD;
&#xD;
               -  Has undergone radical surgery (i.e., mastectomy or conservative surgery) with&#xD;
                  axillary node dissection within the past 7 weeks&#xD;
&#xD;
          -  No inflammatory carcinoma&#xD;
&#xD;
          -  No prior or concurrent ipsilateral or contralateral invasive breast carcinoma&#xD;
&#xD;
          -  No metastatic disease, including metastasis in the ipsilateral supraclavicular lymph&#xD;
             nodes&#xD;
&#xD;
          -  Hormone receptor status not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Menopausal status not specified&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm³&#xD;
&#xD;
          -  WBC ≥ 4,000/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times ULN&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No chronic liver or renal disease&#xD;
&#xD;
          -  No other serious medical illness requiring medication&#xD;
&#xD;
          -  No other malignancy except adequately treated, cone-biopsied in situ carcinoma of the&#xD;
             cervix or basal cell or squamous cell carcinoma of the skin&#xD;
&#xD;
          -  No symptomatic peripheral neuropathy &gt; grade 2&#xD;
&#xD;
          -  No hypersensitivity to study drugs or their components&#xD;
&#xD;
          -  No recent myocardial infarction, congestive heart failure, or serious arrhythmia&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
          -  No prior cytotoxic regimens&#xD;
&#xD;
          -  No prior radiation therapy, except for intraoperative radiation therapy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Venturini, MD</last_name>
    <role>Study Chair</role>
    <affiliation>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy</affiliation>
  </overall_official>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 8, 2007</study_first_submitted>
  <study_first_submitted_qc>February 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2007</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy</investigator_affiliation>
    <investigator_full_name>Lucia Del Mastro,MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

